Bipartisan Senate Bill Aims to Renew Funding for Life-Saving Stem Cell Transplant Program
A bipartisan group of U.S. Senators has introduced legislation to reauthorize funding for the C.W. Bill Young Cell Transplantation Program, a national initiative that connects individuals with blood disorders like sickle cell disease (SCD) and blood cancers with unrelated donors for potentially life-saving stem cell transplants.
The Stem Cell Therapeutic and Research Reauthorization Act of 2026, introduced on March 19, 2026, is sponsored by Senators Jack Reed (D-RI), Tim Scott (R-SC), Tina Smith (D-MN), and James Lankford (R-OK). A companion bill, H.R. 5160, was introduced in the House of Representatives in September 2025.
The Importance of the C.W. Bill Young Cell Transplantation Program
The C.W. Bill Young Cell Transplantation Program, established in 1987, maintains a national registry of over 42 million potential volunteer donors and hundreds of thousands of cord blood units. This registry is crucial for patients who do not have a matched donor within their family – a situation that affects approximately 75% of those needing a transplant.
According to the National Marrow Donor Program (NMDP), the program has facilitated nearly 150,000 transplants since its inception, a 33% increase in the last five years.
Stem Cell Transplants and Sickle Cell Disease
Hematopoietic stem cell transplants (HSCTs), often referred to as bone marrow transplants, involve replacing a patient’s diseased blood-forming cells with healthy cells from a donor. For individuals with sickle cell disease – a genetic disorder affecting red blood cells – a stem cell transplant can offer a potential cure by enabling the body to produce healthy red blood cells.
Stem cell transplants are likewise a standard treatment for various blood cancers, including leukemia, and lymphoma.
Program Success and Continued Need for Reauthorization
The NMDP reports that approximately 99% of adults with common blood cancers now have a suitable donor match thanks to the program’s extensive registry. However, continued funding and reauthorization are essential to maintain this success and expand access to potentially life-saving treatments.
“The goal of the Program has always been to help patients find their life-saving donor — a mission that remains as critical and urgent as ever,” said Amy Ronneberg, CEO of NMDP. She emphasized the program’s role as a “gold standard of public-private partnership” in saving American lives.
How to Become a Donor
The NMDP encourages healthy adults, particularly those aged 18 to 35, to consider joining the national volunteer donor registry. More information is available on the organization’s website.